A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer

Sponsor
Clinical Research Center for Solid Tumor, Korea
Study ID
NCT00830245
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To assess the efficacy and safety of erlotinib for non-small cell lung cancer patients with leptomeningeal carcinomatosis

Key Dates

First listed
Jan 27, 2009
Start date
Jan 31, 2009
Status verified
Jul 2011
Primary completion
Jul 31, 2011
Completion
Jul 31, 2011

Study Design

Enrollment
20 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Erlotinib
    Erlotinib 150mg/day (if no negative conversion --\> increment to 250mg/day)

Primary Outcome Measure

Overall survival [ Time Frame: 1 year ]

Related Studies